Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Acta Physiol Hung ; 94(1-2): 19-30, 2007 Mar.
Article de Anglais | MEDLINE | ID: mdl-17444273

RÉSUMÉ

BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) regulates normal extracellular matrix (ECM) metabolism and it is a key regulator of the fibrotic process. Both angiotensin II (Ang II) and angiotensin IV (Ang IV) have been reported to stimulate PAI-1 expression. It is not known how PAI-1 expression is regulated by the renin-angiotensin system (RAS) in renal tubular cells. METHODS: To dissect signaling mechanisms contributing to the up-regulation of the PAI-1 promoter, porcine proximal tubular cells stably expressing the rabbit AT1 receptor (LLC-PK/AT1) were transiently transfected with a luciferase reporter construct containing the PAI-1 promoter. Promoter activation was assessed by measuring luciferase activity from cell lysates. RESULTS: Ang II dose-dependently stimulated the transcriptional activity of the PAI-1 promoter in renal proximal tubular cells whereas Ang IV had no consistent effect on the promoter activity. Neither inhibition of the Extracellular Signal Regulated Kinase (ERK) cascade nor inhibition of the c-Jun-N-terminal Kinase (JNK) pathway did reduce the stimulation of the PAI-1 promoter by Ang II. However, genistein, a tyrosine kinase inhibitor blocked the effect of Ang II. CONCLUSION: Ang II but not Ang IV activates the PAI-1 promoter in renal proximal tubular cells and this effect is mediated by tyrosine kinases.


Sujet(s)
Angiotensine-II/physiologie , Cellules épithéliales/physiologie , Tubules contournés proximaux/cytologie , Inhibiteur-1 d'activateur du plasminogène/biosynthèse , Récepteur de type 1 à l'angiotensine-II/physiologie , Angiotensine-II/analogues et dérivés , Angiotensine-II/pharmacologie , Animaux , Cellules cultivées , Cellules épithéliales/effets des médicaments et des substances chimiques , Extracellular Signal-Regulated MAP Kinases/physiologie , Génistéine/pharmacologie , JNK Mitogen-Activated Protein Kinases/physiologie , Régions promotrices (génétique)/effets des médicaments et des substances chimiques , Protein-tyrosine kinases/antagonistes et inhibiteurs , Lapins , Récepteur de type 1 à l'angiotensine-II/biosynthèse , Sus scrofa , Transfection , Facteur de croissance transformant bêta/physiologie
2.
J Biotechnol ; 88(3): 251-8, 2001 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-11434970

RÉSUMÉ

beta-galactosidase reporter plasmids containing different viral or minimal promoters are commonly used to correct variable transfection efficiencies in transient transfection experiments. The transcriptional activity of these promoters is thought to be stable under most circumstances. To determine if expression of beta-galactosidase from the commonly used beta-galactosidase plasmids remains stable upon stimulation of the cells with agonists we performed transient transfection experiments. CHO cells stably expressing the rat AT(1A) receptor were transfected with RSVbeta- or CMVbeta- or pTKbeta plasmids alone or together with a reporter construct in which luciferase transcription is driven by the c-fos promoter. Luciferase and/or beta-galactosidase activity was measured from the lysate of cells treated with angiotensin II or serum. We found that agonists increased the transcriptional activity of the different beta-galactosidase plasmids. The effect of angiotensin II and serum was different on the different promoters. Finally, cotransfection of other plasmids also modulated beta-galactosidase activity. These agonist induced variations of beta-galactosidase activity may influence the analysis and interpretation of the results in a systematic manner. Consequently we conclude that the use of a second reporter system to control for transfection efficiency in certain types of experiments may lead to a systematic error and is questionable as a general procedure.


Sujet(s)
Gènes rapporteurs , Luciferases/génétique , Plasmides/génétique , Transfection , beta-Galactosidase/génétique , Angiotensine-II/métabolisme , Animaux , Protocoles de polychimiothérapie antinéoplasique , Phosphates de calcium/composition chimique , Lignée cellulaire , Cricetinae , Cricetulus , Cyclophosphamide , Doxorubicine , Expression des gènes , Régulation de l'expression des gènes , Gènes fos , Plasmides/administration et posologie , Plasmides/isolement et purification , Rats , Récepteur de type 1 à l'angiotensine-II , Récepteurs aux angiotensines/métabolisme , Normes de référence , Transduction du signal , Vincristine , beta-Galactosidase/composition chimique
3.
Exp Nephrol ; 9(2): 142-9, 2001.
Article de Anglais | MEDLINE | ID: mdl-11150863

RÉSUMÉ

To study the role of extracellular-signal-regulated kinase (ERK) cascade and the small GTP-ase proteins in the activation of the c-fos promoter by angiotensin II (AII), transient transfection experiments were performed in CHO cells stably expressing the rat AT(1A) receptor. In this system AII activated ERK in 1 min and also increased the transcriptional activity of the c-fos promoter-luciferase reporter gene construct. The activation of the promoter proved to be dependent on the Ras-Raf-ERK cascade as cotransfection of expression vectors known to specifically inhibit this cascade blocked the effect of AII. Dominant-negative p21Rac1 mutant partially blocked the activation of the c-fos promoter by AII. However, activation of the c-fos promoter was independent of protein kinase C (PKC) as bisindolylmaleimide I, a specific PKC inhibitor did not block the effect of AII. These results suggest that AII activates the transcription of the c-fos through the Ras-Raf-ERK cascade. Furthermore, p21Rac1 is involved in the modulation of the c-fos promoter by AII.


Sujet(s)
Angiotensine-II/physiologie , Mitogen-Activated Protein Kinases/physiologie , Transcription génétique/physiologie , Protéine G rac1/physiologie , Animaux , Cellules CHO , Cricetinae , Phosphatidylinositol 3-kinases/physiologie , Régions promotrices (génétique)/physiologie , Protéine kinase C/physiologie , Protéines proto-oncogènes c-fos/génétique , Protéines proto-oncogènes c-raf/physiologie , Récepteur de type 1 à l'angiotensine-II , Récepteur de type 2 à l'angiotensine-II , Récepteurs aux angiotensines/physiologie , Protéines G ras/physiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE